Magazine Article | March 1, 2021

Companies To Watch: PhaseBio

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Climbing from platform prover to biopharma player

SNAPSHOT

PhaseBio is a small public company aiming to enter a large-market therapeutic area: cardiovascular. Each of its cardiovascular drugs addresses a significant unmet medical need. They include bentracimab, in a Phase 3 trial for reversing ticagrelor’s antiplatelet activity in major bleeding or to enable urgent surgery, and PB6440, an oral selective aldosterone synthase inhibitor in preclinical development for treatment-resistant hypertension. Another lead drug, pemziviptadil, a once-weekly VPAC2-selective agonist in Phase 2 for treating pulmonary arterial hypertension (PAH), is integrated with an extended-action technology, ELP (elastin-like polypeptides).

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: